查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100293

正子斷層掃描（PET）市場－2026-2032年全球市場預測

Positron Emission Tomography Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，正子斷層掃描 (PET) 市場將成長至 33.9 億美元，複合年成長率為 6.56%。

主要市場統計數據
基準年 2025 21.7億美元
預計年份：2026年 23.1億美元
預測年份 2032 33.9億美元
複合年成長率 (%) 6.56%

正子斷層掃描（PET）已成為精準診斷的關鍵支柱，它能夠在常規影像學揭示結構變化之前，可視化代謝、分子和生理活動。在腫瘤、神經、循環系統和發炎性疾病的評估中，PET 可支持早期檢測、分期、治療反應評估、復發評估和治療方案製定。混合型 PET/CT 和 PET/MRI 系統的日益普及、檢測器靈敏度的提高、飛行時間（TOF）成像技術的進步、放射性藥物研發管線的擴展以及臨床對定量影像生物標記日益成長的需求，都在推動著這一領域的發展。監管和臨床指南不斷強化 PET 在實證醫學中的作用，尤其是在癌症管理、失智症評估、心肌活力評估、感染疾病和發炎影像以及治療診斷學（整合治療和診斷工作流程）方面。在整個醫療保健系統中，重點正從單純的影像擷取轉向綜合分子成像過程，該過程結合了放射性示踪劑的可用性、掃描儀性能、標準化方案、人工智慧驅動的影像解釋、輻射安全和多學科決策。

PET領域的變革性變化

隨著醫療服務提供者從孤立的影像檢查轉向序列化、定量化和與治療相關的診斷，正子斷層掃描（PET）領域正在經歷一場變革。混合影像仍然是核心，PET/CT廣泛用於解剖定位和分期，而PET/MRI在需要軟組織對比和降低輻射暴露的特定應用中日益重要。數位檢測器技術、矽光電倍增器、改進的飛行時間（TOF）測量能力以及高靈敏度掃描儀使得掃描時間更短、放射性更低、病灶檢出靈敏度更高成為可能。放射性藥物的創新也是一個重要因素，它拓展了PET的應用範圍，從基於氟代脫氧葡萄糖（FDG）的成像擴展到前列腺特異性膜抗原（PSMA）成像、澱粉樣蛋白和Tau蛋白成像、生長抑制素受體成像、缺氧成像、心臟灌注示踪、感染疾病成像以及標靶治療的伴隨診斷。在操作方面，該領域正在適應同位素複雜的物流、迴旋加速器和發生器的使用、放射化學品質要求、輻射防護標準以及放射性藥物生產的監管控制。影像學、核子醫學、腫瘤學、神經病學、循環系統和治療性放射性藥物的融合，正使PET不僅成為獨立的診斷測試，更成為一個決策平台。

人工智慧對PET的累積影響

人工智慧 (AI) 對整個 PET 流程的影響日益顯著，涵蓋影像擷取、重建、定量分析、工作流程最佳化和臨床解讀等各個環節。基於 AI 的重建和去噪技術，在經過檢驗和監管後，有助於在保持影像品質的同時，實現低劑量或短時 PET 掃描。在影像分析領域，機器學習工具正被開發用於輔助病灶檢測、分割、標準化攝取值 (SUV) 評估、放射組學特徵提取、衰減校正以及隨時間推移的反應比較。 AI 還支援患者預約管理、掃描器利用率最佳化、方案選擇、劑量計劃、影像品質檢查和品管警報等操作應用。在腫瘤學和神經病學領域，研究人員正在探索利用 AI 驅動的 PET 分析來改善風險分層、治療反應預測、疾病進展評估，並整合病理學、基因組學、實驗室結果和電子健康記錄資訊。這些努力共同建構了一個數據更加豐富的 PET 生態系統。然而，負責任的實施需要透明的模型檢驗、偏差評估、與影像標準的互通性、網路安全措施、臨床醫生監督以及遵守醫療設備和放射性藥物的監管要求。

關於寵物收養的關鍵區域見解

在亞太地區，PET 的應用正在穩步推進，這得益於不斷完善的癌症診療基礎設施、日益​​成長的核醫學培訓以及主要都市區迴旋加速器網路的普及。該地區的大部分臨床活動由中國、日本、印度、韓國和澳洲推動。在歐洲，成熟的核子醫學標準、跨境研究合作、放射性藥物監管以及 PET 在腫瘤學、神經病學、循環系統和治療診斷學（一種整合治療和診斷的方法）中的廣泛臨床應用都是優勢，儘管其應用程度會因各國醫保政策、人力資源和同位素供應基礎設施的不同而有所差異。在北美，由於主要適應症的醫保報銷機製完善、強大的核醫學學術計畫、PET/CT 的廣泛普及以及新型放射性示蹤劑的快速臨床應用，PET 的應用仍然非常先進。在拉丁美洲，PET 的應用也在不斷擴展，儘管存在一些差異，巴西和墨西哥是重要的中心。另一方面，在小規模的經濟體中，由於PET服務依賴放射性藥物的配送、專業人員、資本密集設備和轉診網路，因此取得PET服務仍面臨挑戰。在非洲，由於缺乏迴旋加速器基礎設施、放射性藥物物流問題、勞動力短缺和成本障礙，PET服務的取得仍然有限，儘管一些國家正在透過公共部門計畫、與學術機構的合作以及區域轉診模式來建立核醫能力。在中東，透過對三級醫院、癌症中心和先進影像診斷的投資，PET能力正在加強，國家醫療保健現代化策略正在促進分子影像技術的更廣泛應用，尤其是在高所得海灣國家的醫療保健系統中。

全球PET網路關鍵群體分析

北美和歐洲的北約成員國中存在著許多先進的PET生態系統。在這些地區，先進的醫院基礎設施、放射性物質資源、學術核醫學計畫和公共衛生研究能力間接提升了分子影像學的專業水平，但PET在臨床應用中的主要驅動力是私人醫療機構的需求。七國集團（G7）的特點是擁有完善的PET臨床路徑、先進的影像學研究、品質保證體系，以及PET在腫瘤學、神經病學、循環系統和治療診斷學（整合治療和診斷醫學）等領域決策中更緊密的整合。金磚國家的情況則有顯著差異。中國和印度正在主要城市擴大PET的覆蓋範圍，而巴西和俄羅斯則保持著重要的核子醫學能力。南非也是非洲重要的專業影像中心，但農村地區的PET普及、放射性示蹤劑的分發、保險報銷和同位素物流仍是限制其發展的重大因素。歐盟受益於統一的監管原則、協作的臨床研究網路以及支持PET標準化、放射性藥物監管、輻射防護和多中心影像試驗的通用品質框架。在東協地區，PET的發展集中在擁有先進的三級醫療網路、都市區癌症中心和完善的醫療旅遊生態系統的經濟特區，儘管在掃描儀的可用性、放射性示踪劑的生產、熟練人員的配備以及保險報銷體系的成熟度方面仍然存在區域差異。在海灣合作理事會（GCC）國家，PET服務正透過對癌症治療、核子醫學科室和高階醫院基礎設施的投資而不斷發展，這得益於國家醫療現代化計劃、早期疾病檢測的努力以及對精準腫瘤學日益成長的興趣。

主要國家正子斷層掃描（PET）的發展趨勢

在中國，隨著國內放射性藥物研發活動的活性化以及對腫瘤、神經病學和診療一體化成像需求的成長，主要醫院和都市區醫療系統的PET容量正在迅速擴大。美國擁有最發達的PET生態系統之一，這得益於PET/CT的廣泛部署、成熟的核醫學專業知識、在腫瘤學領域的廣泛應用、多種臨床適應症的明確醫保覆蓋以及對失智症和診療一體化成像日益成長的臨床興趣。日本擁有悠久的PET專業技術，尤其是在腫瘤學、神經病學和研究影像領域，這得益於高品質的影像標準、先進的醫療基礎設施以及使用放射性示踪劑進行臨床研究的豐富經驗。在印度，隨著癌症治療的擴展、對私人診斷的投資、三級醫療機構的發展以及人們對分子成像認知的提高，PET在主要城市的普及率正在提高，儘管在都市區，PET的普及率仍然不均衡。德國擁有成熟的核子醫學基礎設施，具備強大的臨床和研究能力，尤其是在腫瘤學、神經影像學、心臟影像影像學和治療診斷學。在英國，PET已納入國家癌症治療路徑以及特定的神經系統和心臟疾病適應症，重點在於循證轉診標準、放射性藥物管治和統一的服務計劃。在澳大利亞，已建立完善的PET網路，專注於腫瘤學以及特定的神經系統和心臟疾病適應症，服務集中在主要醫院和大都會圈，並積極採納臨床指南。在法國，先進的PET服務透過醫院網路、系統性的核子醫學法規以及在癌症分期和療效評估中的廣泛臨床應用得以維持。在韓國，PET的應用正在穩步推進，這得益於現代化的醫院系統、全面的癌症護理項目、先進的診斷基礎設施以及積極的分子影像臨床研究。在義大利和西班牙，PET已深度融入癌症診斷和療效評估，並得到專業影像中心、核子醫學專家和臨床指南的支持。在加拿大，強大的PET計畫依賴學術機構和醫院，其應用受到省級醫療保健資金、迴旋加速器分配、集中式核醫計畫和區域轉診模式的影響。在俄羅斯，核子醫學技術和PET基礎設施已在各大醫療中心得到完善，但地理範圍和區域資源分配影響了公平取得這些服務的機會。巴西擁有大規模的腫瘤治療需求和專業的診斷網路，是拉丁美洲主要的PET中心，但區域差異仍然顯著。在墨西哥，PET的應用正在不斷擴展，尤其是在腫瘤治療領域，尤其是在主要大都會圈，但成本效益、保險報銷差異以及放射性示踪劑的物流等因素影響了其更廣泛的普及。

為PET產業領導者提供的實用建議

產業領導者應優先考慮能夠提升臨床價值、營運韌性和監管應對力的PET策略。醫療機構可以透過標準化影像方案、加強多學科協作、投資培訓核醫學專業人員以及將PET的使用與循證轉診途徑相結合來加速PET的普及應用。影像中心應評估數位PET、飛行時間（TOF）性能、劑量最佳化、定量報告和人工智慧驅動的重建技術，評估標準不僅包括技術創新，還包括檢驗的臨床結果。放射性藥物相關人員應關注可靠的同位素供應、規範的生產、低溫運輸和準時制物流、輻射安全、品管以及針對腫瘤學、神經病學、循環系統、感染疾病成像和治療診斷學需求的多樣化示踪劑組合。政策制定者和保險公司可以透過將保險覆蓋範圍的決策與臨床效用證據、患者預後改善和品質保證標準掛鉤，來支持合理取得PET。技術開發人員應設計可互通的人工智慧和影像診斷平台，使其與既定的醫學影像標準相容，同時保持透明度、可審計性、網路安全和管治，並讓臨床醫生參與其中。整個生態系統最可行的未來發展路徑是建立一個整合的PET服務模型，將示蹤劑供應、掃描儀最佳化、標準化影像擷取、定量報告、資料管治和以病患為中心的診療路徑連接起來。

調查方法

本執行摘要採用結構化的二級研究途徑編寫，重點檢驗、公開且臨床認可的資訊來源。該調查方法強調同行評審的醫學文獻、核醫學學會指南、監管文件、醫保報銷和醫療保健政策參​​考資料、醫院實踐標準、放射性藥物安全要求、輻射防護指南以及來自經認證的公共衛生和科學組織的出版物。證據評估標準包括臨床相關性、時效性、可重複性、地理適用性和跨多個可靠資訊來源的一致性。本分析不涉及市場規模計算、市場預測、市場佔有率和未來展望，而是專注於技術趨勢、臨床應用模式、監管影響、基礎設施需求和區域可及性。透過對PET在腫瘤學、神經病學、循環系統、發炎成像、放射性藥物創新、混合成像、人工智慧、定量成像和治療診斷學等領域的應用進行主題評估，整合了相關見解。從區域、群體和國家層面定性地組織觀點，以反映醫療保健基礎設施、保險報銷制度的成熟度、同位素物流、專業人員的可用性、監管能力和臨床整合狀況；不提出任何推測性的商業性預測。

結論

正子斷層掃描（PET）正從專門的診斷方法發展成為精準醫療、分子影像和治療指南護理的重要組成部分。當高品質的影像系統、可靠的放射性藥物供應、標準化的操作流程、專業的影像解讀、輻射安全以及定量資料的跨學科應用被整合到臨床路徑中時，其價值將最為顯著。人工智慧、數位PET技術、新型放射性追蹤劑以及治療診斷學（治療性診斷）應用正在改變PET在早期診斷、個人化治療選擇和治療反應監測方面的貢獻方式。同時，仍存在諸多挑戰，包括全球可及性差異、同位素物流、人力資源限制、保險報銷差異、放射性藥物生產的複雜性以及對人工智慧工具進行嚴格檢驗的必要性。優先考慮臨床證據、營運品質、法規遵從性和公平可及性的相關人員將更有利於推進PET在現代醫學中的作用，同時提高診斷可靠性和以病人為中心的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 正子斷層掃描（PET）市場：依產品類型分類

  • 裝置
    • 專用PET掃描儀
    • PET/CT掃描儀
  • 放射性示踪劑

第8章 正子斷層掃描（PET）市場：依應用領域分類

  • 循環系統
  • 神經病學
  • 腫瘤學

第9章 正子斷層掃描（PET）市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 研究機構

第10章 正子斷層掃描（PET）市場：依檢測器技術分類

  • 閃爍體型PET系統
  • 採用溶菌酶晶體的PET系統
  • 採用BGO晶體的PET系統
  • 配備矽光電倍增器（SiPM）的PET系統

第11章 正子斷層掃描（PET）市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章 正子斷層掃描（PET）市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章 正子斷層掃描（PET）市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Cubresa Inc.
  • GE HealthCare Technologies Inc.
  • Hitachi Ltd.
  • Koninklijke Philips NV
  • Mediso Ltd.
  • MILabs BV
  • MinFound Medical Systems Co., Ltd
  • MR Solutions Ltd.
  • Neusoft Medical Systems Co., Ltd.
  • PerkinElmer, Inc.
  • Positron Corporation
  • Segami Corporation
  • Shanghai United Imaging Healthcare Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sofie Biosciences, Inc.
  • Toshiba Corporation
  • TRIVITRON Healthcare
  • United Imaging Healthcare Co., Ltd.
  • Yangzhou Kindsway Biotech Co.,Ltd.
Product Code: MRR-742BD5183E5A

The Positron Emission Tomography Market is projected to grow by USD 3.39 billion at a CAGR of 6.56% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.17 billion
Estimated Year [2026] USD 2.31 billion
Forecast Year [2032] USD 3.39 billion
CAGR (%) 6.56%

Positron Emission Tomography (PET) has become a critical pillar of precision diagnostics by enabling clinicians to visualize metabolic, molecular, and physiologic activity before many structural changes are apparent on conventional imaging. In oncology, neurology, cardiology, and inflammatory disease assessment, PET supports earlier detection, staging, therapy response evaluation, recurrence assessment, and treatment planning. The field is being shaped by wider adoption of hybrid PET/CT and PET/MRI systems, advances in detector sensitivity and time-of-flight imaging, expanding radiopharmaceutical pipelines, and growing clinical demand for quantitative imaging biomarkers. Regulatory and clinical guidance continue to reinforce PET's role in evidence-based care, particularly for cancer management, dementia evaluation, myocardial viability assessment, infection and inflammation imaging, and theranostic workflows. Across health systems, the emphasis is shifting from image acquisition alone toward integrated molecular imaging pathways that combine radiotracer availability, scanner performance, standardized protocols, artificial intelligence-enabled interpretation, radiation safety, and multidisciplinary decision-making.

Transformative Shifts in the PET Landscape

The positron emission tomography landscape is undergoing transformative change as healthcare providers move from episodic imaging toward longitudinal, quantitative, and therapy-linked diagnostics. Hybrid imaging remains central, with PET/CT widely used for anatomic localization and staging, while PET/MRI is gaining relevance in selected applications requiring soft-tissue contrast and reduced radiation exposure. Digital detector technologies, silicon photomultipliers, improved time-of-flight capability, and higher sensitivity scanners are supporting faster acquisitions, lower administered activity, and improved lesion detectability. Radiopharmaceutical innovation is another major shift, extending PET beyond fluorodeoxyglucose-based imaging into prostate-specific membrane antigen imaging, amyloid and tau imaging, somatostatin receptor imaging, hypoxia imaging, cardiac perfusion tracers, infection imaging, and companion diagnostics for targeted therapies. Operationally, the sector is adapting to complex isotope logistics, cyclotron and generator access, radiochemistry quality requirements, radiation protection standards, and regulatory controls for radiopharmaceutical production. The convergence of imaging, nuclear medicine, oncology, neurology, cardiology, and therapeutic radiopharmaceuticals is positioning PET as a decision-support platform rather than a standalone diagnostic test.

Cumulative Impact of Artificial Intelligence on PET

Artificial intelligence is increasingly influencing PET across acquisition, reconstruction, quantification, workflow orchestration, and clinical interpretation. AI-based reconstruction and denoising methods can support lower-dose or shorter-duration PET scans while preserving image quality, subject to validation and regulatory oversight. In image analysis, machine learning tools are being developed to assist lesion detection, segmentation, standardized uptake value assessment, radiomics feature extraction, attenuation correction, and longitudinal response comparison. AI also supports operational use cases such as patient scheduling, scanner utilization, protocol selection, dose preparation planning, image quality checks, and quality control alerts. In oncology and neurology, AI-enabled PET analytics are being investigated for improved risk stratification, treatment response prediction, disease progression assessment, and integration with pathology, genomics, laboratory results, and electronic health records. The cumulative impact is a more data-rich PET ecosystem; however, responsible deployment requires transparent model validation, bias assessment, interoperability with imaging standards, cybersecurity safeguards, clinician oversight, and alignment with medical device and radiopharmaceutical regulatory requirements.

Key Regional Insights for PET Adoption

Asia-Pacific is experiencing rising PET adoption supported by expanding oncology care infrastructure, increasing nuclear medicine training, and growing access to cyclotron networks in major urban centers, with China, Japan, India, South Korea, and Australia driving much of the region's clinical activity. Europe benefits from mature nuclear medicine standards, cross-border research collaboration, radiopharmaceutical regulation, and broad clinical integration of PET in oncology, neurology, cardiology, and theranostic pathways, although adoption varies by reimbursement policy, workforce capacity, and isotope supply infrastructure across countries. North America remains highly advanced in PET utilization due to established reimbursement pathways for major indications, strong academic nuclear medicine programs, broad PET/CT availability, and rapid clinical translation of new radiotracers. Latin America shows uneven but expanding PET capacity, with Brazil and Mexico serving as important hubs while access challenges persist across smaller economies because PET services depend on radiopharmaceutical distribution, specialized staff, capital-intensive equipment, and referral networks. Africa continues to face constrained PET access due to limited cyclotron infrastructure, radiopharmaceutical logistics, workforce shortages, and affordability barriers, though selected countries are building nuclear medicine capacity through public-sector programs, academic partnerships, and regional referral models. The Middle East is strengthening PET capabilities through investment in tertiary hospitals, cancer centers, and advanced diagnostic imaging, particularly in high-income Gulf health systems, where national health modernization strategies are supporting broader use of molecular imaging.

Key Group Insights Across Global PET Networks

NATO member countries include many advanced PET ecosystems in North America and Europe, where sophisticated hospital infrastructure, radiological preparedness capabilities, academic nuclear medicine programs, and public health research capacity indirectly reinforce molecular imaging expertise, although clinical PET adoption is primarily driven by civilian healthcare needs. G7 countries are characterized by established PET clinical pathways, advanced imaging research, quality assurance systems, and stronger integration of PET into oncology, neurology, cardiology, and theranostic decision-making. BRICS countries demonstrate significant heterogeneity: China and India are expanding PET access in major cities, Brazil and Russia maintain important nuclear medicine capabilities, and South Africa serves as a key African center for specialized imaging, while rural access, radiotracer distribution, reimbursement, and isotope logistics remain persistent constraints. The European Union benefits from harmonized regulatory principles, collaborative clinical research networks, and shared quality frameworks that support PET standardization, radiopharmaceutical oversight, radiation protection, and multicenter imaging trials. Within ASEAN, PET development is concentrated in economies with stronger tertiary care networks, urban cancer centers, and medical tourism ecosystems, while regional disparities remain linked to scanner availability, radiotracer production, specialist workforce capacity, and reimbursement maturity. The GCC is advancing PET services through investments in cancer care, nuclear medicine departments, and high-end hospital infrastructure, with demand supported by national health modernization programs, early disease detection initiatives, and growing interest in precision oncology.

Key Country Insights in Positron Emission Tomography

China is rapidly expanding PET capacity in leading hospitals and urban healthcare systems, with growing domestic radiopharmaceutical activity and rising demand for oncology, neurology, and theranostic imaging. The United States has one of the most developed PET ecosystems, supported by extensive PET/CT availability, established nuclear medicine expertise, broad oncology use, defined coverage for multiple clinical indications, and growing clinical interest in dementia and theranostic imaging. Japan has long-standing PET expertise, particularly in oncology, neurology, and research imaging, supported by high-quality imaging standards, advanced healthcare infrastructure, and extensive experience with radiotracer-based clinical research. India is increasing PET availability across major cities, driven by cancer care expansion, private diagnostic investment, tertiary hospital development, and greater awareness of molecular imaging, though access remains uneven outside urban centers. Germany has a mature nuclear medicine base with strong clinical and research capabilities, especially in oncology, neuroimaging, cardiac imaging, and theranostics. The United Kingdom integrates PET into national cancer pathways and selected neurologic and cardiac indications, with emphasis on evidence-based referral criteria, radiopharmaceutical governance, and centralized service planning. Australia operates a well-developed PET network focused on oncology and selected neurologic and cardiac indications, with services concentrated in major hospitals and metropolitan centers and supported by strong clinical guideline adoption. France maintains advanced PET services through hospital networks, structured nuclear medicine regulation, and broad clinical use in cancer staging and treatment response assessment. South Korea has advanced PET adoption supported by modern hospital systems, strong cancer care programs, sophisticated diagnostic infrastructure, and active clinical research in molecular imaging. Italy and Spain both show strong PET integration in cancer diagnosis and treatment response assessment, supported by specialist imaging centers, nuclear medicine expertise, and clinical guidelines. Canada demonstrates strong academic and hospital-based PET programs, with access shaped by provincial healthcare funding, cyclotron distribution, centralized nuclear medicine planning, and regional referral models. Russia has established nuclear medicine expertise and PET infrastructure in major centers, while geographic scale and regional resource distribution affect equitable access. Brazil is Latin America's major PET center, supported by large oncology demand and specialized diagnostic networks, though regional disparities remain significant. Mexico is expanding PET use in major metropolitan areas, particularly for oncology, while affordability, reimbursement variation, and radiotracer logistics influence wider access.

Actionable Recommendations for PET Industry Leaders

Industry leaders should prioritize PET strategies that strengthen clinical value, operational resilience, and regulatory readiness. Healthcare providers can improve adoption by standardizing imaging protocols, enhancing multidisciplinary collaboration, investing in nuclear medicine workforce training, and aligning PET utilization with evidence-based referral pathways. Imaging centers should evaluate digital PET, time-of-flight performance, dose optimization, quantitative reporting, and AI-enabled reconstruction based on validated clinical outcomes rather than technology novelty alone. Radiopharmaceutical stakeholders should focus on reliable isotope supply, compliant production, cold-chain and just-in-time logistics, radiation safety, quality control, and diversified tracer portfolios aligned with oncology, neurology, cardiology, infection imaging, and theranostic needs. Policymakers and payers can support appropriate access by linking coverage decisions to clinical utility evidence, patient outcome improvement, and quality assurance standards. Technology developers should design interoperable AI and imaging platforms compatible with established medical imaging standards, while maintaining transparency, auditability, cybersecurity, and clinician-in-the-loop governance. Across the ecosystem, the most actionable path forward is to build integrated PET service models that connect tracer availability, scanner optimization, standardized acquisition, quantitative reporting, data governance, and patient-centered care pathways.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, publicly available, and clinically recognized sources. The methodology emphasizes peer-reviewed medical literature, nuclear medicine society guidance, regulatory documentation, reimbursement and health policy references, hospital practice standards, radiopharmaceutical safety requirements, radiation protection guidance, and publications from recognized public health and scientific institutions. Evidence is assessed for clinical relevance, recency, reproducibility, geographic applicability, and consistency across multiple credible sources. The analysis excludes market sizing, market estimation, market share, and forecasting, and instead concentrates on technology trends, clinical adoption patterns, regulatory influences, infrastructure requirements, and regional access dynamics. Insights are synthesized through thematic evaluation of PET applications in oncology, neurology, cardiology, inflammation imaging, radiopharmaceutical innovation, hybrid imaging, artificial intelligence, quantitative imaging, and theranostics. Regional, group, and country perspectives are framed qualitatively to reflect healthcare infrastructure, reimbursement maturity, isotope logistics, specialist workforce availability, regulatory capacity, and clinical integration without presenting speculative commercial projections.

Conclusion

Positron emission tomography is advancing from a specialized diagnostic modality into an essential component of precision medicine, molecular imaging, and therapy-guided care. Its value is strongest where clinical pathways integrate high-quality imaging systems, reliable radiopharmaceutical supply, standardized protocols, expert interpretation, radiation safety, and multidisciplinary use of quantitative data. Artificial intelligence, digital PET technology, novel radiotracers, and theranostic applications are reshaping how PET contributes to earlier diagnosis, personalized treatment selection, and response monitoring. At the same time, persistent challenges remain, including uneven global access, isotope logistics, workforce constraints, reimbursement variability, radiopharmaceutical production complexity, and the need for robust validation of AI-enabled tools. Stakeholders that prioritize clinical evidence, operational quality, regulatory compliance, and equitable access will be best positioned to advance PET's role in modern healthcare while improving diagnostic confidence and patient-centered outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Positron Emission Tomography Market, by Product Type

  • 7.1. Introduction
  • 7.2. Equipment
    • 7.2.1. Dedicated Pet Scanners
    • 7.2.2. PET/CT Scanners
  • 7.3. Radiotracers

8. Positron Emission Tomography Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Neurology
  • 8.4. Oncology

9. Positron Emission Tomography Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals
  • 9.4. Research Institutes

10. Positron Emission Tomography Market, by Detector Technology

  • 10.1. Introduction
  • 10.2. Scintillator-Based PET Systems
  • 10.3. LYSO Crystal-Based PET Systems
  • 10.4. BGO Crystal-Based PET Systems
  • 10.5. Silicon Photomultiplier (SiPM) PET Systems

11. Positron Emission Tomography Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. Positron Emission Tomography Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. Positron Emission Tomography Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Bruker Corporation
  • 15.2. Canon Medical Systems Corporation
  • 15.3. Cardinal Health, Inc.
  • 15.4. Cubresa Inc.
  • 15.5. GE HealthCare Technologies Inc.
  • 15.6. Hitachi Ltd.
  • 15.7. Koninklijke Philips N.V.
  • 15.8. Mediso Ltd.
  • 15.9. MILabs B.V.
  • 15.10. MinFound Medical Systems Co., Ltd
  • 15.11. MR Solutions Ltd.
  • 15.12. Neusoft Medical Systems Co., Ltd.
  • 15.13. PerkinElmer, Inc.
  • 15.14. Positron Corporation
  • 15.15. Segami Corporation
  • 15.16. Shanghai United Imaging Healthcare Co., Ltd.
  • 15.17. Shimadzu Corporation
  • 15.18. Siemens Healthineers AG
  • 15.19. Sofie Biosciences, Inc.
  • 15.20. Toshiba Corporation
  • 15.21. TRIVITRON Healthcare
  • 15.22. United Imaging Healthcare Co., Ltd.
  • 15.23. Yangzhou Kindsway Biotech Co.,Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEDICATED PET SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DEDICATED PET SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DEDICATED PET SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PET/CT SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PET/CT SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PET/CT SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOTRACERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOTRACERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOTRACERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SCINTILLATOR-BASED PET SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SCINTILLATOR-BASED PET SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SCINTILLATOR-BASED PET SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LYSO CRYSTAL-BASED PET SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LYSO CRYSTAL-BASED PET SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LYSO CRYSTAL-BASED PET SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BGO CRYSTAL-BASED PET SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BGO CRYSTAL-BASED PET SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BGO CRYSTAL-BASED PET SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SILICON PHOTOMULTIPLIER (SIPM) PET SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SILICON PHOTOMULTIPLIER (SIPM) PET SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SILICON PHOTOMULTIPLIER (SIPM) PET SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 90. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 96. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 120. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. JAPAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. JAPAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. JAPAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 139. JAPAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. JAPAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. JAPAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. INDIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. INDIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. INDIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 145. INDIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. INDIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. INDIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. GERMANY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. GERMANY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GERMANY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 151. GERMANY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GERMANY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GERMANY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED KINGDOM POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED KINGDOM POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED KINGDOM POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED KINGDOM POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED KINGDOM POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED KINGDOM POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. AUSTRALIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. AUSTRALIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AUSTRALIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. AUSTRALIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. AUSTRALIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AUSTRALIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. FRANCE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. FRANCE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. FRANCE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 169. FRANCE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. FRANCE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. FRANCE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. SOUTH KOREA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. SOUTH KOREA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. SOUTH KOREA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 175. SOUTH KOREA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. SOUTH KOREA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. SOUTH KOREA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ITALY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. ITALY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ITALY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 181. ITALY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ITALY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ITALY POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. RUSSIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MEXICO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. MEXICO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DETECTOR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 215. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025